CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

By sjmartinez • February 28, 2025

Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, Falchook G, Cleary JM, Kim R, Krishnamurthy A, Marathe O, Youssoufian H, Ellis C, Waszak A, Ghosh S, Zhang H, Yablonski K, Shah SD, Diaz-Padilla I, Ulahannan S. CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. BJC Rep. 2025 Feb 27;3(1):10. doi: 10.1038/s44276-024-00118-x. PMID: 40016550.

Tags: Hematology/Oncology, Publications

Related Posts

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study

McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]